Abstract
Dysregulation of circular RNAs (circRNAs) has recently been shown to play important regulatory roles in cancer development and progression, including non-small cell lung cancer (NSCLC). However, the roles of most circRNAs in NSCLC are still unknown. In this study, we found that hsa_circ_0001421 (circ-SEC31A) was upregulated in NSCLC tissues and cell lines. Increased circ-SEC31A expression in NSCLC was significantly correlated with malignant characteristics and served as an independent risk factor for the post-surgical overall survival of NSCLC patients. Reduced circ-SEC31A expression in NSCLC decreased tumor cell proliferation, migration, invasion, and malate-aspartate metabolism. Mechanistically, we demonstrated that silencing circ-SEC31A downregulated GOT-2 expression by relieving the sponging effect of miR-520a-5p, which resulted in significantly reduced malate-aspartate metabolism in NSCLC cells. Taken together, these results revealed the important role of circ-SEC31A in the proliferation, migration, invasion, and metabolic regulation of NSCLC cells, providing a new perspective on circRNAs in NSCLC progression.
Highlights
Lung cancer is a high-risk tumor that is the most common malignancy in the world and seriously endangers human health
High circ-SEC31A expression was associated with increased lymph node metastasis, higher TNM stage, and larger tumor size compared with the low circSEC31A expression group
The level of circ-SEC31A was increased in three non-small cell lung cancer (NSCLC) cell lines (A549, PC9 and H1650), compared with normal lung epithelial cells BEAS-2B, with the highest expression levels observed in A549 and H1650 cells (Figure 1C)
Summary
Lung cancer is a high-risk tumor that is the most common malignancy in the world and seriously endangers human health. It is the most important factor in cancer-related deaths [1, 2]. Lung cancer often has no obvious symptoms in the early stage, as its symptoms and signs appear later, so most patients are in middlelate stages at the time of treatment, and most have local spread or distant metastasis. The overall 5-year survival rate is approximately 15%, while for patients with distant metastasis, the 5-year survival rate is
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
